Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease

American Journal of Epidemiology

Volumn 133, Issue 1, 1991, Pages 32-37

  Gerstman, B Burt ^a   Piper, Joyce M ^b   Tomita, Dianne K ^a   Ferguson, William J ^a   Stadel, Bruce V ^a   Lundin, Frank E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contraceptives; Epidemiologic methods; Oral; Pulmonary embolism; Thrombophlebitis

Indexed keywords

ADULT; ARTICLE; DEEP VEIN THROMBOSIS; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK FACTOR;

CHEMISTRY, PHARMACEUTICAL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; HUMAN; RISK FACTORS; THROMBOEMBOLISM;

EID: 0026078062     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a115799     Document Type: Article

References (32)

1. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305:612-18.
2. Vessey MP. Female hormones and vascular disease— an epidemiological overview. Br J Fam Plann 1980;suppl:1-12.
3. Sartwell PE, Stolley PD. Oral contraceptives and vascular disease. Epidemiol Rev 1982;4:95-109.
4. Piper JM, Kennedy DL. Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol 1987;16:215-21.
5. Gerstman BB, Gross TP, Kennedy DL, et al. Trends in the content and use of oral contraceptives in the United States. Am J Public Health (in press).
6. Inman WHW, Vessey MP, Westerholm B, et al. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ 1970;2:203-9.
7. Stolley PD, Tonascia JA, Tockman MS, et al. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975;102:197-208.
8. Bottinger LE, Bowan G, Eklund G, et al. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; 1:1097-1101.
9. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-/jg oestrogen preparations. BMJ 1980;280:1157-61.
10. Sartwell PE, Masi AT, Arthes FG, et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969,90:365-80.
11. Gerstman BB, Lundin FE, Stadel BV, et al. A method of pharmacoepidemiologic analysis that uses computerized Medicaid data. J Clin Epidemiol (in press).
12. US Department of Health and Human Services. International classification of diseases, injuries, and causes of death. Ninth Revision, Clinical modification. 2nd ed, vol 1. Washington, DC: US Department of Health and Human Services, 1980. (DHHS publication no. (PHS)80-1260).
13. Gerstman BB, Freiman JP, Hine LK. Use of subsequent anticoagulants to increase the predictive value of Medicaid deep venous thromboembolism diagnoses. Epidemiology 1990;1: 122-7.
14. Rothman KJ, Boice JD. Epidemiologic analysis with a programmable calculator. Boston, MA: Epidemiologic Resources, 1982.
15. Miettinen OS. Estimability and estimation in casereferent studies. Am J Epidemiol 1976,103:226-35.
16. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837-49.
17. Breslow NE, Day NE, eds. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. Lyon: International Agency for Research on Cancer, 1980. (IARC scientific publication no. 32).
18. Dean AG, Imrey HH, Dusich K, et al. Adjusting morbidity ratios in two communities using risk factor prevalence in cases. Am J Epidemiol 1988; 127:654-62.
19. Vessey MP. Some methodological problems in the investigation of rare adverse reactions to oral contraceptives. Am J Epidemiol 1971;94:202-9.
20. Barnes RW, Krapf SRN, Hoak JC. Erroneous clinical diagnosis of leg vein thrombosis in women on oral contraceptives. Obstet Gynecol 1978;51:556-8.
21. Griffin MR, Stanson AW, Brown ML, et al. Deep venous thrombosis and pulmonary embolism: risk of subsequent malignant neoplasm. Arch Intern Med 1987; 147:1907-11.
22. Lillienfeld AM, Lillienfeld D. Foundations of epidemiology. New York: Oxford Press, 1980.
23. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. New York: Van Nostrand Reinhold, 1982.
24. Wessler S, Gitel SN, Wan LS, et al. Estrogencontaining oral contraceptive agents: a basis for their thrombogenicity. JAMA 1976;236:2179-82.
25. Sagar S, Stamatakis JD, Thomas DP, et al. Oral contraceptives, antithrombin-II activity, and postoperative deep-vein thrombosis. Lancet 1976;1: 509-11.
26. Stamatakis JD, Lawrence D, Kakkar VV. Surgery, venous thrombosis, and anti-Xa. Br J Surg 1977;64:709-11.
27. Alkjaersig N, Fletcher A, Burstein R. Association between oral contraceptive use and thromboembolism: a new approach to its investigation based on plasma fibrinogen chromatography. Am J Obstet Gynecol 1975;122:199-211.
28. Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988;158:1646-52.
29. Mishell DR. Contraception. N Engl J Med 1989;320:777-87.
30. Russell-Briefel R, Essati T, Perlman J. Prevalence and trends in oral contraceptive use in premenopausal females ages 12-54, United States, 1971. Am J Public Health 1985;75:1173-6.
31. Forrest JD, Fordyce RR. U.S. women's contraceptive attitudes and practices: how have they changed in the 1980s? Fam Plann Perspect 1988;20:112-18.
32. Population Information Program, The Johns Hopkins University. Population reports: lower-dose pills. Vol 16, no. 3, series A, no. 7. Baltimore, MD: Population Information Program, 1989.